Kristie L. Kahl

The Metastatic Breast Cancer Alliance (MBCA) launched a campaign to bring awareness of clinical trials to more individuals and encourage them to speak with their health care teams about them.

Dr. Camillo Porta discussed what is new in kidney cancer beyond the first line of treatment at A Vision of Hope: A Kidney Cancer Educational Symposium.

Now a 10-year survivor of bone cancer, Dana Vaughns chose to triumph over his disease and joined Bristol-Myers Squibb on its Coast 2 Coast 4 Cancer ride.

Those with non-clear cell kidney cancer have much to look forward to as oncologists’ understanding of the disease is evolving.

Pre- and post-surgical treatment could benefit patients with kidney cancer who are at high risk for disease recurrence.

One patient advocate explained how patients with renal cell carcinoma can query about clinical trials and what they need to know about them to do so.

Nutrition plays a key role in kidney cancer; however, the need to address it is still unmet.

One expert explained what patients should know about their kidney cancer diagnosis at A Vision of Hope: A Kidney Cancer Educational Symposium.

Frontline treatment with Opdivo improved overall survival and response rates among patients with advanced hepatocellular carcinoma, however, the trial missed its primary endpoint.

In this episode of the “CURE Talks Cancer” podcast, Twist Out Cancer founder Jenna Benn Shersher shares on her journey with grey zone lymphoma and how her organization helps pair individuals to use art as an outlet to cope through cancer.

The IMvigor130 trial showed chemotherapy plus immunotherapy in patients with metastatic urothelial cancer could prolong the time to disease progression.

Two patients with metastatic breast cancer shared their journeys, inspiring fellow patients at Susan G. Komen Greater New York City’s New York Metastatic Breast Cancer Conference.

A blood test may help to identify the best treatment option for patients with ALK-positive, advanced non-small cell lung cancer, sparing patients from having to undergo an invasive biopsy.

Dr. Patrick I. Borgen discussed estrogen receptor-positive breast cancer and why it is important for patient to understand what this means for their treatment.

A recent study found no different in disease recurrence among men with prostate cancer when they were given radiation after surgery or not.

Phase 3 trial findings showed that treatment with Lynparza delayed disease progression by about four months compared with newer hormonal agents in pre-treated patients with metastatic castration-resistant prostate cancer and faulty DNA repair genes.

In this episode of the "CURE Talks Cancer" podcast, the keynote speaker for the CURE Patient-Focused Sessions at the New York Lung Cancers Symposium shares how a pain under her arm led to her diagnosis in less than 48 hours.

“Survivors living with recurrent breast cancer have unique needs and programs that address these needs can enhance patient satisfaction,” the study authors wrote.

CURE spoke with an expert on how patients can better advocate for themselves when it comes to genetic testing and its follow-up.

Two studies showed that adding a CDK4/6 inhibitor to treatment with Faslodex improved survival among women with hormone receptor-positive, human epidermal growth factor2-negative advanced breast cancer.

First-line Tagrisso significantly extended overall survival compared with first generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer, according to results from the phase 3 FLAURA study.

One in two patients with metastatic melanoma is alive five years following treatment with Opdivo plus Yervoy, according to long-term follow-up of the phase 3 CheckMate 067 trial.

Frontline maintenance therapy with Zejula lengthened time without disease progression among women with newly diagnosed, advanced ovarian cancer, according to findings from the phase 3 PRIMA study.

First-line treatment with Opdivo plus low-dose Yervoy improved survival among patients with advanced NSCLC compared to chemotherapy, according to results from the CheckMate-227 trial.

The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial.

Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.

The Food and Drug Administration expanded its approval of Cologuard, an at-home non-invasive colorectal cancer screening test, to include use among average-risk individuals aged 45 and older.

Here is a list of the recent trial initiations that occurred within the cancer space in September.

A recent survey found that lung cancer stigma can be a barrier to treatment; however, on the plus side, the percentage of people who associate the disease with smoking has dropped in recent years.

CURE spoke with an expert from Mount Sinai to discuss the future of ovarian cancer treatment and his advice for women facing a new diagnosis.